Sequoia Financial Advisors LLC Makes New $67,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Sequoia Financial Advisors LLC bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,605 shares of the company’s stock, valued at approximately $67,000.

A number of other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after acquiring an additional 1,353 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock valued at $53,000 after acquiring an additional 2,387 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at $54,000. Finally, PNC Financial Services Group Inc. raised its position in Recursion Pharmaceuticals by 220.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company’s stock valued at $66,000 after purchasing an additional 6,758 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on RXRX shares. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a research note on Thursday. They issued an “equal weight” rating and a $5.00 price objective on the stock. Needham & Company LLC lowered their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.00.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $5.26 on Friday. The stock has a market capitalization of $2.14 billion, a P/E ratio of -2.97 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The company’s fifty day moving average is $4.84 and its two-hundred day moving average is $6.11.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.39) earnings per share. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.